Advances in next-generation sequencing (NGS) have catalyzed a paradigm shift in cancer treatment, steering the focus from conventional, organ-specific protocols to precision medicine. Emerging targeted therapies offer a cutting-edge approach to cancer treatment, while companion diagnostics play an essential role in aligning therapeutic choices with specific molecular changes identified through NGS. Despite these advances, interpreting the clinical implications of a rapidly expanding catalog of genetic mutations remains a challenge. The selection of therapies in the presence of multiple mutations requires careful clinical judgment, supported by quality-centric genomic testing that emphasizes actionable mutations. Molecular tumor boards can play an increasing role in assimilating genomic data into clinical trials, thereby refining personalized treatment approaches and improving patient outcomes.
新一代测序技术的进步推动了癌症治疗范式的转变，将治疗重点从传统的器官特异性方案转向精准医疗。新兴靶向疗法为癌症治疗提供了前沿手段，而伴随诊断在将治疗选择与通过新一代测序识别的特定分子变化相匹配方面发挥着关键作用。尽管取得这些进展，如何解读快速增长的基因突变目录的临床意义仍面临挑战。在存在多重突变的情况下选择治疗方案需要审慎的临床判断，并需以注重可操作突变的优质基因组检测为支撑。分子肿瘤委员会在将基因组数据整合至临床试验中的作用日益凸显，从而优化个体化治疗方案并改善患者预后。
肿瘤(癌症)患者之家